DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial

Raghav Sundar, Alvin Ng, Hermioni Zouridis, Nisha Padmanabhan, Taotao Sheng, Shenli Zhang, Ming Hui Lee, Wen Fong Ooi, Aditi Qamra, Imran Inam, Lindsay C. Hewitt, Jimmy Bok-Yan So, Vivien Koh, Matthew G. Nankivell, Ruth E. Langley, William H. Allum, David Cunningham, Steven G. Rozen, Wei Peng Yong, Heike I. GrabschPatrick Tan

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)48-57
Number of pages10
JournalEuropean Journal of Cancer
Volume123
DOIs
Publication statusPublished - Dec 2019

Keywords

  • Epigenetic signature
  • DNA methylation
  • Predictive biomarker
  • Chemotherapy
  • Oesophageal adenocarcinoma
  • GASTRIC-CANCER
  • OPEN-LABEL
  • PERIOPERATIVE CHEMOTHERAPY
  • METHYLATION
  • CAPECITABINE
  • RESECTION
  • SURGERY

Cite this

Sundar, R., Ng, A., Zouridis, H., Padmanabhan, N., Sheng, T., Zhang, S., Lee, M. H., Ooi, W. F., Qamra, A., Inam, I., Hewitt, L. C., So, J. B-Y., Koh, V., Nankivell, M. G., Langley, R. E., Allum, W. H., Cunningham, D., Rozen, S. G., Yong, W. P., ... Tan, P. (2019). DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 123, 48-57. https://doi.org/10.1016/j.ejca.2019.09.016